Quest Diagnostics, eMed Team Up To Offer COVID-19 Rapid Antigen Testing At Workplaces

by Vandana Singh, Benzinga Editor

August 11, 2021 1:45 PM | 1 min read |

Telehealth company eMed and Quest Diagnostics Inc DGX have collaborated for clinician-guided rapid antigen testing for COVID-19 in workplaces.
Through the collaboration, the two companies will leverage the BinaxNOW COVID-19 Ag Card Home Test, a self-administered nasal swab antigen test that provides results in 15 minutes.
An eMed Certified Guide will virtually supervise the testing process, confirm employee identity, oversee proper sample collection, and authenticate results during a telehealth visit.
Individuals will receive their validated results via a digital health pass on their smart device, and employers will have access to a portal with consolidated employee test results.
Price Action: DGX shares are up 0.16% at $148.81 during the market session on the last check Wednesday.

Posted In: News Health Care Contracts General Briefs COVID-19 Coronavirus

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.